CMS seeks to expand GLP-1 access for Medicare beneficiaries The Centers for Medicare & Medicaid Services July 1 launched the Medicare GLP-1 Bridge, a short-term demonstration program designed to provide eligible Medicare Part D beneficiaries with access to certain GLP-1 medications through Dec
The only tangentially relevant data comes from amphetamine studies where BPC-157 counteracted stereotypy and prevented behavioral sensitization, but amphetamine-induced stereotypy models psychosis and stimulant abuse, not ADHD symptoms
One capsule daily, taken with food in the morning
These observations have clear clinical implications in future studies of GSH as a protector against CDDP toxicity
A previous study indicated that treatment with the GLP-1 agonist liraglutide (subcutaneously at a dose gradually titrated from 0.6 to 3 mg) in bipolar and mood disorder depression patients could result in an improvement in cognitive function and an alleviation of depressive pathological symptoms (Cuomo et al., 2018)
These effects are particularly important to understand for patients with underlying digestive disorders like ulcerative colitis